Welcome to the Emerging Pathogens & Infectious Diseases Consortium
Welcome to EPIC – the Emerging Pathogens and Infectious Diseases Consortium.
EPIC brings together researchers, clinicians, and institutions across the University of Toronto and its hospital partners to advance infectious disease research and build lasting resilience against emerging threats.
This work builds on a long legacy: EPIC partners have played an integral role in infectious disease research for a century, from work that helped control diphtheria and eradicate smallpox, to today’s front-line research in antimicrobial resistance and infection control. Our collective response to COVID-19, highly pathogenic avian influenza, and mpox makes clear there’s never been a more important time to advance that work, from emerging pathogens and antimicrobial resistance to health inequities and public trust.
Building on this momentum, EPIC marshals the advanced research infrastructure and world-renowned research and training expertise of our EPIC partners to deliver an integrated, innovative response to the infectious disease challenges facing communities today and in the future.
Seven EPIC research clusters
Antimicrobial resistance
Protecting the effectiveness of the medicines we depend on.
Chronic infections and long-term sequelae
Addressing the long-term burden of infections that don’t resolve.
Emerging and re-emerging pathogens
Detecting and responding to new and re-emerging threats before they spread.
Health inequities
Ensuring infectious disease research and response reach everyone, equitably.
Health systems resilience
Building health systems that bend, not break, under infectious threats.
Misinformation, disinformation and public trust
Strengthening public trust through clear, credible information.
Sepsis and acute infections
Improving detection and treatment when every minute counts.
EPIC News
U of T Infectious Diseases and Microbiology Research Day returns in-person after three-year hiatus
Some of the trainee speakers at the 2023 Infectious Diseases and Microbiology Research Day. (Back row: l-r) James Pollock, Cynthia Guo (Middle row: l-r) Krithika Muthuraman, Derek Tsang, Jonathon Kotwa, Priyal Shah, Natalie Au, Purav Guptal (Front row) Emma Lash June...
EPIC Researcher Mobility Awards enable immersive international training experiences for doctoral students and postdoctoral fellows
The Emerging and Pandemic Infections Consortium has announced the eight recipients of its inaugural Researcher Mobility Awards. These awards provide financial support to doctoral students and postdoctoral fellows to undertake research training or to complete collaborative field work outside of Toronto.
Landon J. Getz receives inaugural GSK EPIC Convergence Postdoctoral Fellowship in Antimicrobial Resistance
EPIC is pleased to announce Landon J. Getz as the recipient of the inaugural GSK EPIC Convergence Fellowship in Antimicrobial Resistance (AMR). Established through a generous gift from GlaxoSmithKline (GSK), the fellowship will support Getz’s innovative and cross-disciplinary research that aims to address the growing threat of AMR through the development of phage therapy.
